Welcome to our dedicated page for Savara news (Ticker: SVRA), a resource for investors and traders seeking the latest updates and insights on Savara stock.
Savara Inc. (SVRA) is a clinical-stage biopharmaceutical company pioneering inhaled therapies for rare respiratory diseases. This page serves as the definitive source for official announcements, clinical trial updates, and regulatory developments related to their innovative pipeline targeting conditions like cystic fibrosis and autoimmune pulmonary alveolar proteinosis.
Investors and healthcare professionals will find timely updates on Phase 3 clinical trials, FDA regulatory milestones, and strategic partnerships in respiratory drug development. Our curated news collection provides essential context about SVRA's novel dry powder antibiotics and nebulized biologic therapies while maintaining strict compliance with financial disclosure standards.
Key updates include progress reports on Aerovanc™ for MRSA lung infections, molgramostim nebulizer solution developments, and analyses of market positioning within rare disease therapeutics. All content is verified through primary sources to ensure accuracy for investment research and medical community reference.
Bookmark this page for consolidated access to Savara's latest corporate announcements, peer-reviewed research collaborations, and therapeutic advancement timelines. Check regularly for objective updates on breakthrough inhalation technologies addressing critical needs in pulmonary medicine.
Savara Inc. (Nasdaq: SVRA) has announced the dosing of the first patient in the pivotal IMPALA-2 clinical trial, designed to evaluate the efficacy and safety of molgramostim for autoimmune pulmonary alveolar proteinosis (aPAP). This Phase 3 trial will enroll approximately 160 patients across ~50 sites globally. Despite the previous IMPALA trial not meeting its primary endpoint, supportive secondary data showed potential benefits of molgramostim. The FDA granted Breakthrough Therapy Designation for molgramostim in aPAP in December 2019, highlighting its significance in addressing unmet medical needs.
Savara Inc. (Nasdaq: SVRA), a biopharmaceutical company specializing in rare respiratory diseases, has announced its participation in the Jefferies Virtual Healthcare Conference. The presentation is scheduled for June 2, 2021, at 10:00 AM ET. Interested parties can access the live audio webcast on Savara's Investors page, with an archived version available for 90 days post-event. The company’s primary focus is on its molgramostim nebulizer solution, currently in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
Savara Inc. (Nasdaq: SVRA) announced its participation in the Oppenheimer Rare & Orphan Disease Virtual Summit scheduled for May 21, 2021, at 12:25 PM ET. The management will present information about the company's focus on rare respiratory diseases, particularly its lead program, molgramostim nebulizer solution, which is in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Interested parties can access the live audio webcast on Savara's website.
Archived presentations will be available for 90 days following the event.
Savara Inc. (Nasdaq: SVRA) announced on May 11, 2021, the granting of stock options and restricted stock units (RSUs) to a new employee. This includes options to purchase 175,000 shares at an exercise price of $1.62, the closing price on the grant date. The options will vest quarterly over four years, while the RSUs will fully vest after two years. Savara specializes in developing treatments for rare respiratory diseases, focusing on its lead program, molgramostim, currently in Phase 3 for autoimmune pulmonary alveolar proteinosis.
Savara Inc. (Nasdaq: SVRA) reported a net loss of $10.2 million or $(0.13) per share for Q1 2021, an improvement from a loss of $15.4 million or $(0.27) per share in Q1 2020. The company reduced R&D expenses by 42.5% to $7.6 million, mainly due to the absence of costs related to the acquisition of Apulmiq. Savara raised $130 million in equity, enhancing its cash position to approximately $193 million, expected to fund operations through 2025. The IMPALA-2 trial's site activation is underway, with early patient randomization anticipated by late Q2 or early Q3 2021.
Savara Inc. (Nasdaq: SVRA) announced the completion of an underwritten public offering of 57,479,978 shares of common stock at $1.45 each, raising approximately $130 million before fees. This includes 11,694,150 shares purchased via underwriters' full exercise of their option. Additionally, pre-funded warrants for 32,175,172 shares were sold at $1.449 each. The funds will be allocated towards operational costs, particularly for the clinical development of molgramostim in autoimmune pulmonary alveolar proteinosis and broader working capital needs.
Savara Inc. (Nasdaq: SVRA) has announced the pricing of an underwritten public offering of 45,785,828 shares at $1.45 each, yielding expected gross proceeds of approximately $113 million. Additionally, the company offered pre-funded warrants for 32,175,172 shares at $1.449 each. Proceeds will fund working capital for clinical, regulatory, and commercial activities, particularly related to its molgramostim nebulizer solution for autoimmune pulmonary alveolar proteinosis. The offering is set to close on March 15, 2021, pending customary conditions.
Savara Inc. (Nasdaq: SVRA) announced its intention to offer shares of common stock in an underwritten public offering, also providing certain investors with the option to purchase pre-funded warrants. Proceeds from this offering will primarily support working capital, including clinical development and regulatory activities related to its molgramostim nebulizer for autoimmune pulmonary alveolar proteinosis (aPAP). The offering is subject to market conditions and the underwriters have a 30-day option to purchase an additional 15% of the offering. Jefferies LLC and Piper Sandler are managing the offering.
Savara Inc. (Nasdaq: SVRA) announced updates on its pipeline and company operations, aiming to focus resources on Molgradex for autoimmune pulmonary alveolar proteinosis (aPAP) and the Phase 3 IMPALA 2 trial. The company discontinued the AeroVanc program after failing to meet primary endpoints in the AVAIL trial. Operating expenses will be reduced, including workforce cuts, while cash reserves are expected to be approximately $82 million. The IMPALA 2 trial's start has been pushed to Q2 2021 due to COVID-19 impacts.
Savara Inc. (Nasdaq: SVRA) has announced its participation in upcoming virtual fireside chats at key investor healthcare conferences. The Piper Sandler Annual Healthcare Conference will feature a recorded chat available until December 3, 2020, with a replay on Savara's website. Additionally, the Evercore ISI Annual HealthCONx Conference is scheduled for December 3, 2020, at 12:35 PM EST, with a live webcast accessible online. Both events will have replays for 90 days. Savara focuses on orphan lung diseases, with three investigational inhaled compounds in development.
FAQ
What is the current stock price of Savara (SVRA)?
What is the market cap of Savara (SVRA)?
